Juraj Kultan

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Petra Zemanová et al. · Anticancer Research · 2020 · 86 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Jana Skřičková et al. · Anticancer Research · 2018 · 41 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Ondřej Fiala, Miloš Pešek, Jana Skřičková et al. · Tumor Biology · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacology +13

Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience

Milada Zemanová, Robert Pirker, Luboš Petruželka et al. · Radiology and Oncology · 2020 · 13 citations · Full text

Medicine, Nuclear Medicine, Oncology +14